Research programme: therapeutic antibodies and peptides - Dyax/MerckAlternative Names: Therapeutic antibodies and peptides research programme - Dyax/Merck
Latest Information Update: 19 Mar 2010
At a glance
- Originator Dyax; Merck & Co
- Developer Merck & Co
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 29 Aug 2005 Preclinical trials in Undefined in USA (unspecified route)